Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Hutchmed
Deal Size : $608.0 million
Deal Type : Divestment
HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture
Details : The proceeds will used to develop its pipeline and strategy including its next-generation ADCs for treating patients suffering from cancers.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : $608.0 million
January 01, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Hutchmed
Deal Size : $608.0 million
Deal Type : Divestment
Lead Product(s) : BCD-100,Pemetrexed,Cisplatin
Therapeutic Area : Oncology
Study Phase : Phase III
Recipient : Biocad
Deal Size : Not Applicable
Deal Type : Not Applicable
Clinical Trial of An Original Russian Drug for The Treatment of Lung Cancer Starts in China
Details : The BIOCAD and Shanghai Pharmaceuticals Holding joint venture has announced enrollment of patient with treatment prolgolimab in BCD-100-3/DOMAJOR clinical trial of an original anti-PD1 check point inhibitor in patients with non-small cell lung cancer (NS...
Product Name : BCD-100
Product Type : Large molecule
Upfront Cash : Not Applicable
October 13, 2021
Lead Product(s) : BCD-100,Pemetrexed,Cisplatin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : Biocad
Deal Size : Not Applicable
Deal Type : Not Applicable
Reset All
